Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

Bruce L. Levine,Marcelo C. Pasquini,John E. Connolly,David L. Porter,Michael P. Gustafson, Jaap J. Boelens,Edwin M. Horwitz,Stephan A. Grupp,Marcela V. Maus,Frederick L. Locke,Fabio Ciceri,Annalisa Ruggeri,John Snowden,Helen E. Heslop,Crystal L. Mackall,Carl H. June,Anna M. Sureda,Miguel-Angel Perales

Nature Medicine（2024）

引用 0|浏览4

暂无评分

摘要

Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要